LDLR and cancer: Overall, increased LDL-cholesterol uptake mediated by LDLR upregulation, possibly accompanied by elevated expression and activity of LE/Lys-Chol transporters (NPC1, StARD3, and ORPs), lysosomal LE/Lys-Chol binding proteins (LAMP2, LIMP2) and regulators (Rab GTPases), often coincides with increased cancer growth, metastatic behavior and chemoresistance.